← Back to Search

18F-FluorThanatrace PET/CT Imaging for Prostate Cancer

Phase < 1
Waitlist Available
Led By Dan Pryma, MD
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be ≥ 18 years of age
Participants must have biopsy-proven prostate cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new imaging technique to see if it can accurately find where prostate cancer is in the body.

Who is the study for?
Men over 18 with biopsy-proven prostate cancer, who have at least one tumor lesion of 1 cm or larger. They must be recommended for a prostatectomy or oligometastectomy and willing to provide tissue samples for research. Excluded are those unable to tolerate imaging, with serious health/psychological issues, or unable to give informed consent.
What is being tested?
The study tests a new PET/CT imaging method using [18F]FluorThanatrace (FTT) to measure PARP-1 activity in primary or metastatic prostate cancer sites. The results will be compared with pathology findings from surgeries like prostatectomies.
What are the potential side effects?
[18F]FluorThanatrace is used for imaging and may cause discomfort at the injection site, allergic reactions, and exposure to radiation typical of PET/CT scans which carries a small risk of future cancer.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My prostate cancer diagnosis was confirmed through a biopsy.
Select...
I am recommended to undergo surgery for prostate cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort 3Experimental Treatment2 Interventions
Gleason 9 or oligometastic disease (n=10)
Group II: Cohort 2Experimental Treatment2 Interventions
Gleason 7-8 (n=10)
Group III: Cohort 1Experimental Treatment2 Interventions
Gleason 6 (n=10)

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
108,474 Total Patients Enrolled
12 Trials studying Prostate Cancer
2,287 Patients Enrolled for Prostate Cancer
Abramson Cancer Center at Penn MedicineLead Sponsor
413 Previous Clinical Trials
164,601 Total Patients Enrolled
15 Trials studying Prostate Cancer
2,535 Patients Enrolled for Prostate Cancer
Dan Pryma, MDPrincipal InvestigatorAbramson Cancer Center at Penn Medicine
1 Previous Clinical Trials
6 Total Patients Enrolled

Media Library

Poly(ADP Ribose) Polymerase 1 Clinical Trial Eligibility Overview. Trial Name: NCT03334500 — Phase < 1
Prostate Cancer Research Study Groups: Cohort 3, Cohort 1, Cohort 2
Prostate Cancer Clinical Trial 2023: Poly(ADP Ribose) Polymerase 1 Highlights & Side Effects. Trial Name: NCT03334500 — Phase < 1
Poly(ADP Ribose) Polymerase 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT03334500 — Phase < 1
~5 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top